A Descriptive Analysis of Fatal Outcomes in Immune Thrombotic Thrombocytopenic Purpura in the USTMA TTP Registry

Overview

Journal Blood Adv

Specialty Hematology

Date 2023 Dec 15

PMID 38100454

Authors

Mouhamed Yazan Abou-Ismail

Chong Zhang

Angela P Presson

Shruti Chaturvedi

Ana G Antun

Andrew M Farland

Ryan Woods

Ara Metjian

Yara A Park

Gustaaf de Ridder

Briana Gibson

Raj S Kasthuri

Darla K Liles

Frank Akwaa

Todd Clover

Lisa Baumann Kreuziger

Meera Sridharan

Ronald S Go

Keith R McCrae

Harsh Vardhan Upreti

Radhika Gangaraju

Nicole K Kocher

X Long Zheng

Jay S Raval

Camila Masias

Spero R Cataland

Andrew D Johnson

Elizabeth Davis

Michael D Evans

Marshall Mazepa

Ming Y Lim

Affiliations

Soon will be listed here.

Citing Articles

Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.

Fianchi L, Bonanni M, Borchiellini A, Valeri F, Giuffrida G, Grasso S J Clin Med. 2024; 13(21).

PMID: 39518700 PMC: 11546578. DOI: 10.3390/jcm13216561.

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.

Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A Res Pract Thromb Haemost. 2024; 8(3):102388.

PMID: 38651093 PMC: 11033197. DOI: 10.1016/j.rpth.2024.102388.

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.

Wei R, Wu Y, Jiang S, Zhang A, Zhang L, Liu L Clin Exp Med. 2023; 23(8):4609-4621.

PMID: 37925380 PMC: 10725366. DOI: 10.1007/s10238-023-01231-w.

References

Goel R, King K, Takemoto C, Ness P, Tobian A . Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion. 2016; 56(6):1451-8. PMC: 5537726. DOI: 10.1111/trf.13586. View

Scully M, Cataland S, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga J . Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019; 380(4):335-346. DOI: 10.1056/NEJMoa1806311. View

Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bige N . A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2020; 137(6):733-742. PMC: 7986049. DOI: 10.1182/blood.2020008021. View

Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga J . Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021; 5(8):2137-2141. PMC: 8095153. DOI: 10.1182/bloodadvances.2020001834. View

Colling M, Sun L, Upadhyay V, Ryu J, Li A, Uhl L . Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 2020; 60(4):841-846. DOI: 10.1111/trf.15721. View

Benhamou Y, Assie C, Boelle P, Buffet M, Grillberger R, Malot S . Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica. 2012; 97(8):1181-6. PMC: 3409815. DOI: 10.3324/haematol.2011.049676. View

Westwood J, Thomas M, Alwan F, McDonald V, Benjamin S, Lester W . Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2018; 1(15):1159-1166. PMC: 5728327. DOI: 10.1182/bloodadvances.2017008268. View

Khalil F, Ali M, Ellithi M . Impact of Acute Coronary Syndrome on Clinical Outcomes in Patients With Thrombotic Thrombocytopenic Purpura. Cureus. 2023; 15(3):e35878. PMC: 10079805. DOI: 10.7759/cureus.35878. View

Chaturvedi S, Antun A, Farland A, Woods R, Metjian A, Park Y . Race, rituximab, and relapse in TTP. Blood. 2022; 140(12):1335-1344. PMC: 9710186. DOI: 10.1182/blood.2022016640. View

10.

Zheng X, Vesely S, Cataland S, Coppo P, Geldziler B, Iorio A . Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18(10):2503-2512. PMC: 7880820. DOI: 10.1111/jth.15009. View

11.

Akwaa F, Antun A, Cataland S . How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge. Blood. 2022; 140(5):438-444. DOI: 10.1182/blood.2021014514. View

12.

Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S . Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017; 130(4):466-471. DOI: 10.1182/blood-2016-12-758656. View

13.

Cuker A, Cataland S, Coppo P, Rubia J, Friedman K, George J . Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021; 137(14):1855-1861. DOI: 10.1182/blood.2020009150. View